A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

D. Demetri, George; G. Casali, Paolo; Blay, Jean‐Yves; von Mehren, Margaret; A. Morgan, Jeffrey; Bertulli, Rossella; Ray‐Coquard, Isabelle; A. Cassier, Philippe; Davey, Monica; Borghaei, Hossein; Pink, Daniel; Dêbiec‐Rychter, Maria; K. Cheung, Wing; M. Bailey, Stuart; Luisa Veronese, Maria; Reichardt, Annette; Fumagalli, Elena; Reichardt, Peter

doi:10.1158/1078-0432.ccr-09-0542

Public

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

Published in Clinical Cancer Research • Sep 1, 2009

Authors:

George D. Demetri

Paolo G. Casali

Jean‐Yves Blay

Abstract

PURPOSE: To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib in patients with advanced imatinib-resistant gastrointestinal stromal tumors. EXPERIMENTAL DESIGN: A phase I intercohort dose-escala...

Subject

Nilotinib

Medicine

Imatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!